Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Journal of Drug Issues is Scopus-indexed (Q2, CiteScore 3.3), WoS SSCI. It is covered by India's One Nation One Subscription scheme for reading access. Published by SAGE Publications Inc..
Checked against the index lists dated .
ISSN 0022-0426Verify ISSN ↗1945-1369Verify ISSN ↗
Publisher: SAGE Publications Inc.
Cost to publish: About US$3,650 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Health (social science) | 143 / 387 | 63rd | Q2 |
| Medicine (miscellaneous) | 187 / 466 | 59th | Q2 |
| Public Health, Environmental and Occupational Health | 310 / 725 | 57th | Q2 |
| Psychiatry and Mental Health | 283 / 580 | 51st | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1971–present, best quartile Q2, CiteScore 3.3.
Journal of Drug Issues is Q2 in Health (social science) (rank 143 of 387), Q2 in Medicine (miscellaneous) (rank 187 of 466) and Q2 in Public Health, Environmental and Occupational Health (rank 310 of 725), by CiteScore 2025. It is ranked in 4 subject areas in all.
Journal of Drug Issues is indexed in the Social Sciences Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.3, which places it in quartile Q2 at the 63rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.575, quartile Q2, with an H-index of 64.
The publisher lists an article processing charge of about US$3,650 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Journal of Drug Issues is published by SAGE Publications Inc. Its print ISSN is 0022-0426 and its online ISSN is 1945-1369.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Social Sciences Citation Index.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Journal of Drug Issues has an h-index of 88 and a 2-year mean of 0.99 citations per paper (OpenAlex). Its Scopus CiteScore is 3.3, quartile Q2. On 2-year citations it ranks #222 of 378 Scopus journals in Health (social science).
Journal of Drug Issues published 54 papers in 2025; its busiest recent year was 2022 with 59. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2024–2026), authors are most often from United States (54.3%), Australia (5.2%) and Israel (4.6%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 3 retracted papers are recorded (1.2 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.